Literature DB >> 29129052

Synthesis and Evaluation of Orexin-1 Receptor Antagonists with Improved Solubility and CNS Permeability.

David A Perrey1, Ann M Decker1, Yanan Zhang1.   

Abstract

Orexins are hypothalamic neuropeptides playing important roles in many functions including the motivation of addictive behaviors. Blockade of the orexin-1 receptor has been suggested as a potential strategy for the treatment of drug addiction. We have previously reported OX1 receptor antagonists based on the tetrahydroisoquinoline scaffold with excellent OX1 potency and selectivity; however, these compounds had high lipophilicity (clogP > 5) and low to moderate solubility. In an effort to improve their properties, we have designed and synthesized a series of analogues where the 7-position substituents known to favor OX1 potency and selectivity were retained, and groups of different nature were introduced at the 1-position where substitution was generally tolerated as demonstrated in previous studies. Compound 44 with lower lipophilicity (clogP = 3.07) displayed excellent OX1 potency ( Ke = 5.7 nM) and selectivity (>1,760-fold over OX2) in calcium mobilization assays. In preliminary ADME studies, 44 showed excellent kinetic solubility (>200 μM), good CNS permeability ( Papp = 14.7 × 10-6 cm/sec in MDCK assay), and low drug efflux (efflux ratio = 3.3).

Entities:  

Keywords:  ADME; Orexin; antagonist; selective; tetrahydroisoquinoline

Mesh:

Substances:

Year:  2017        PMID: 29129052      PMCID: PMC6002953          DOI: 10.1021/acschemneuro.7b00402

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  40 in total

Review 1.  Chemistry and biology of orexin signaling.

Authors:  Thomas Kodadek; Di Cai
Journal:  Mol Biosyst       Date:  2010-06-07

Review 2.  Orexin receptor antagonists: a new concept in CNS disorders?

Authors:  John Gatfield; Catherine Brisbare-Roch; Francois Jenck; Christoph Boss
Journal:  ChemMedChem       Date:  2010-08-02       Impact factor: 3.466

Review 3.  Selective orexin receptor antagonists.

Authors:  Terry P Lebold; Pascal Bonaventure; Brock T Shireman
Journal:  Bioorg Med Chem Lett       Date:  2013-07-04       Impact factor: 2.823

4.  Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor.

Authors:  David A Perrey; Nadezhda A German; Ann M Decker; David Thorn; Jun-Xu Li; Brian P Gilmour; Brian F Thomas; Danni L Harris; Scott P Runyon; Yanan Zhang
Journal:  ACS Chem Neurosci       Date:  2015-02-12       Impact factor: 4.418

Review 5.  Multiple roles for orexin/hypocretin in addiction.

Authors:  Stephen V Mahler; Rachel J Smith; David E Moorman; Gregory C Sartor; Gary Aston-Jones
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

6.  Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.

Authors:  Konstantin Kuteykin-Teplyakov; Carlos Luna-Tortós; Kamila Ambroziak; Wolfgang Löscher
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 7.  Orexin receptor antagonists: medicinal chemistry and therapeutic potential.

Authors:  Anthony J Roecker; Paul J Coleman
Journal:  Curr Top Med Chem       Date:  2008       Impact factor: 3.295

Review 8.  Suvorexant: first global approval.

Authors:  Lily P H Yang
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

9.  Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor.

Authors:  David A Perrey; Nadezhda A German; Brian P Gilmour; Jun-Xu Li; Danni L Harris; Brian F Thomas; Yanan Zhang
Journal:  J Med Chem       Date:  2013-08-26       Impact factor: 7.446

Review 10.  Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls.

Authors:  Jiann Wei Yeoh; Erin J Campbell; Morgan H James; Brett A Graham; Christopher V Dayas
Journal:  Front Neurosci       Date:  2014-02-25       Impact factor: 4.677

View more
  3 in total

Review 1.  Therapeutics development for addiction: Orexin-1 receptor antagonists.

Authors:  David A Perrey; Yanan Zhang
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

2.  Demand elasticity predicts addiction endophenotypes and the therapeutic efficacy of an orexin/hypocretin-1 receptor antagonist in rats.

Authors:  Morgan H James; Hannah E Bowrey; Colin M Stopper; Gary Aston-Jones
Journal:  Eur J Neurosci       Date:  2018-10-14       Impact factor: 3.386

3.  Neuropeptide B/W receptor 1 peptidomimetic agonists: Structure-activity relationships and plasma stability.

Authors:  Thuy Nguyen; Ann M Decker; Rodney W Snyder; Emma C Tonetti; Thomas F Gamage; Yanan Zhang
Journal:  Eur J Med Chem       Date:  2022-01-21       Impact factor: 6.514

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.